Genzyme

	WikiDoc Resources for Genzyme
Articles
Most recent articles on Genzyme Most cited articles on Genzyme Review articles on Genzyme Articles on Genzyme in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Genzyme Images of Genzyme Photos of Genzyme Podcasts & MP3s on Genzyme Videos on Genzyme
Evidence Based Medicine
Cochrane Collaboration on Genzyme Bandolier on Genzyme TRIP on Genzyme
Clinical Trials
Ongoing Trials on Genzyme at Clinical Trials.gov Trial results on Genzyme Clinical Trials on Genzyme at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Genzyme NICE Guidance on Genzyme NHS PRODIGY Guidance FDA on Genzyme CDC on Genzyme
Books
Books on Genzyme
News
Genzyme in the news Be alerted to news on Genzyme News trends on Genzyme
Commentary
Blogs on Genzyme
Definitions
Definitions of Genzyme
Patient Resources / Community
Patient resources on Genzyme Discussion groups on Genzyme Patient Handouts on Genzyme Directions to Hospitals Treating Genzyme Risk calculators and risk factors for Genzyme
Healthcare Provider Resources
Symptoms of Genzyme Causes & Risk Factors for Genzyme Diagnostic studies for Genzyme Treatment of Genzyme
Continuing Medical Education (CME)
CME Programs on Genzyme
International
Genzyme en Espanol Genzyme en Francais
Business
Genzyme in the Marketplace Patents on Genzyme
Experimental / Informatics
List of terms related to Genzyme

Template:Infobox Company

Genzyme Corporation is a biotechnology company based in Cambridge, Massachusetts. Genzyme is the world’s third biggest biotechnology company employing over 9,000 people around the world. At present, the company has approximately 80 locations in 40 countries. It includes 17 manufacturing facilities and 9 genetic testing laboratories. The company’s products are available in nearly 90 countries. In 2006, Genzyme generated $3.2 billion in revenues with more than 25 products in the world’s markets. The company is also involved in philanthropic acts, donating $83 million in global product donations and $11 million in cash contributions in 2006. In 2006 and 2007 Genzyme was named one of Fortune Magazine’s “100 Best Companies to Work for.” Additionally in 2007, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the President of the United States to America’s leading innovators.

The company, started by a small group of scientists in 1981, was primarily devoted to finding drugs that would cure enzyme deficiency conditions that were essential to one’s survival and which usually afflict a very small percentage of the world’s population. Drugs used to treat such conditions are termed “orphan drugs.” In 1986, the company went public raising $27 million.

Genzyme focuses on six areas of medicine relating to lysosomal storage diseases, renal disease, orthopedics, transplant and immune diseases, oncology, genetics and diagnostics. The first orphan-drug for Genzyme that FDA approved was Ceredase, a drug for treating Gaucher disease. Other important drugs made by Genzyme are Renagel, used in treatment of dialysis patients, and Fabrazyme, used to treat patients with Fabry's disease. Other products in development are Tolevamer for Clostridium dificile colitis disease and Campath for multiple sclerosis.

Genzyme has a sub-license from Bioenvision to market Clofarabine in North America. Bioenvision has the rights to Clofarabine in the rest of the world. On Tuesday, May 29, 2007 Genzyme made a tender offer to purchase Bioenvision for $5.60 per share. Bioenvision management and the board of directors tendered their shares via an agreement prior to the announcement. However, not many other shareholders did and the tender offer closed without Genzyme acquiring their necessary 51% of Bioenvision. It remains to be seen if Genzyme will just be a shareholder of Bioenvision or proceed with a higher subsequent offer.

In 2006, CEO, President, and Board Chairman Henri Termeer, earned a salary of $1.4 million, and non-cash compensation worth $21 million.^[1]